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Modulation of the immune response with tumor necrosis factor (TNF) blockers is not a new treatment strategy
for many inflammatory disorders; however, relatively little is known about their specific mechanism of action.
Understanding the mode of action, pharmacology, and pharmacokinetics of the monoclonal TNF antibodies,
infliximab and adalimumab, and the soluble TNF receptor, etanercept, may therefore enable us to account for
their differing clinical profiles. The aim of this supplement is to explore the roles and mechanisms of TNF and
TNF blockade using in vitro pharmacological and in vivo animal modeling experiments, and in vivo studies of
the effects of etanercept on the inflammatory cascade in patients with psoriasis.
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INTRODUCTION
Tumor necrosis factor (TNF) blockers revolutionized the care
of patients with multiple immune disorders, including
rheumatoid arthritis (Maini et al., 1998; Lorenz et al., 2000;
Rau, 2002), psoriasis (Chaudhari et al., 2001; Leonardi et al.,
2003; Gottlieb et al., 2004; Patel and Gordon, 2004; Tyring
et al., 2006), psoriatic arthritis (Mease et al., 2004, 2005;
Antoni et al., 2005), ankylosing spondylitis (Braun et al.,
2002), and inflammatory bowel disease (Crohn’s disease
(Targan et al., 1997; Baldassano et al., 2003; Hanauer et al.,
2006) and ulcerative colitis (Akobeng, 2006)). Currently,
there are three biologics that block TNF approved in the
United States for the treatment of various inflammatory
disorders. Infliximab and adalimumab are both monoclonal
anti-TNF antibodies; etanercept is a soluble TNF receptor-Fc
fusion protein. Despite the clinical availability of these life-
altering drugs for many years, relatively little is known about
their mechanisms of action in patients. If all TNF blockers
were merely ‘‘sponges’’, sopping up excess TNF in inflam-
matory conditions, then one could not explain why the three
TNF-blocking biologics show differing efficacy and safety
profiles as outlined in Table 1. Understanding the mechan-
isms of action, pharmacokinetics, and pharmacodynamics
may explain the observed differences in safety and efficacy
profiles (Table 1).
There are different approaches that can be taken to
understand potential mechanism of action differences that
may account for observed clinical differences. These include
in vitro pharmacology experiments, animal modeling and
studies in patients treated with TNF-blocking drugs. The
effect of TNF blockade on the growth of opportunistic
organisms in vitro, on granuloma formation, and on the
activation of immune defense mechanisms in vitro is reported
in this supplement.
Wallis et al. (published in this supplement) examine the
effects of all three TNF-blocking drugs in vitro on the immune
response to and growth of Mycobacterium tuberculosis using
human whole-blood cultures. Infliximab and adalimumab
reduced the proportion of tuberculosis-responsive cells by 70
and 50%, respectively, and suppressed antigen-induced IFN-g
production by 70 and 64%, respectively. In contrast,
etanercept produced no significant effect in these measures.
Intracellular survival of M. tuberculosis was much higher in
whole blood cultured with either monoclonal anti-TNF
antibody compared with etanercept. Neither apoptosis nor
differential induction of IL-10 was observed in whole-blood
cultures with any of the three TNF-blocking drugs. In
contrast, Ehlers et al. (published in this supplement) could
not demonstrate any difference among the three TNF-
blocking biologics in the induction of human monocyte
death by M. tuberculosis infection in vitro.
Haider et al. (published in this supplement) used gene
array analysis to study the effects of etanercept or infliximab
when cultured in the presence of human peripheral blood
mononuclear cells, which were activated with a combination
of anti-CD3 and anti-CD28 antibodies. The expression of
only 29 genes was suppressed by both etanercept and
infliximab. Etanercept suppressed the expression of 55
unique genes. In contrast, 513 genes were suppressed by
only infliximab. The authors stated that differing pharmaco-
logic activity may explain the observed clinical differences
between etanercept and infliximab.
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Kohno et al. (published in this supplement) reported that
etanercept formed smaller complexes with TNF than did the
monoclonal anti-TNF antibodies. These authors postulated
that etanercept was a less flexible molecule than the
monoclonal antibodies and therefore steric hindrance pre-
vented formation of larger complexes.
Animal studies can be used to study mechanisms of both
efficacy and adverse events. Animal studies of the host
response to tuberculosis and other opportunistic infections are
reported by a number of investigators in this supplement. TNF
is essential for granuloma formation and thus for host defenses
against mycobacteria and other granulomatous pathogens
(Flynn et al., 1995; Wallis et al., 2004; Ehlers, 2005).
Deepe (published in this supplement) summarizes the
dependency of containment of both primary and secondary
Histoplasma capsulatum infection on TNF. In the presence of
murine monoclonal anti-TNF antibodies, there is increased
death of mice secondary to H. capsulatum infection. The
role of TNF and its receptors in the host immune response to
H. capsulatum was dissected using a number of knockout
mouse models.
Studies in patients treated with TNF blockade sequestering
agents use blood and target organ tissues that are sampled at
multiple time points before and during treatment. An early
step in the psoriatic cascade is dendritic cell (DC) activation
and maturation, stimulating T-cell activation that leads to a
predominant T-helper type 1 inflammatory response. Lympho-
cytes, DCs, neutrophils, keratinocytes, and possibly other
cells produce additional cytokines, growth factors, and
chemokines that result in a sustained pattern of inflammation
and the formation of psoriatic plaques (reviewed by Gottlieb,
2005; Gottlieb et al., 2005; Lizzul et al., 2005). From gene
studies and histological analysis, Tan et al. demonstrated in
this supplement and elsewhere that TNF/lymphotoxin block-
ade induced by etanercept interrupts this self-sustaining
derangement, reverses cutaneous inflammation, and pro-
motes plaque clearance. This is achieved by the down-
regulation of multiple inflammatory pathways. TNF inhibition
Table 1. TNF blockade: clinical differences in safety and efficacy1
TNF blocker Efficacy Safety
Etanercept In a published clinical trial of Crohn’s disease, patients receiving
etanercept for 8 weeks did not show a statistically significant response
compared with patients receiving placebo (Sandborn et al., 2001; Haraoui,
2005).
Review of the scientific literature suggests that there is a
difference in incidence of tuberculosis in patients receiving
infliximab versus patients receiving etanercept (Gomez-
Reino et al., 2003; Wallis et al., 2004; Akkoc et al., 2006;
GEAR Rheumatoid Arthritis Study Group, 2006; Opris et al.,
2006; Ryan et al., 2006; Tegzova et al., 2006).
In published clinical trials, 44–49% of patients receiving etanercept 50 mg
twice weekly achieved PASI 75 at week 12 (Leonardi et al., 2003; Papp
et al., 2005; Tyring et al., 2006).
Statistically significant differences in the PASI 75 response rates between
the etanercept 50 mg BIW group and the placebo group were reported as
early as week 4 (Papp et al., 2005).
In the United States, higher initial dosing is indicated for psoriasis patients
compared with psoriatic arthritis or rheumatoid arthritis patients (GEAR
Rheumatoid Arthritis Study Group, 2006).
Infliximab Effective for Crohn’s disease and ulcerative colitis (Targan et al., 1997;
Hanauer et al., 2002).
Review of the scientific literature suggests that there is a
difference in incidence of tuberculosis in patients receiving
infliximab versus patients receiving etanercept
(Gomez-Reino et al., 2003; Wallis et al., 2004; Akkoc et al.,
2006; GEAR Rheumatoid Arthritis Study Group, 2006;
Opris et al., 2006; Ryan et al., 2006; Tegzova et al., 2006).
In published clinical trials of patients with psoriasis, at week 10, 80–88% of
patients receiving the 5 mg/kg dose achieved a PASI 75 (Chaudhari et al.,
2001; Reich et al., 2005).
More infliximab-treated patients than placebo-treated patients achieved
PASI 75 by week 6 (Reich et al., 2005).
Adalimumab Has shown clinical benefit in patients with Crohn’s disease (Sandborn
et al., 2004; Papadakis et al., 2005).
Reports in the scientific literature have not shown that there
is a difference in incidence of tuberculosis in patients
receiving adalimumab and infliximab (Keystone et al.,
2004; Bakleh et al., 2005; Gottlieb et al., 2005; Winthrop
et al., 2005; Schiff et al., 2006).
1No head-to-head, well-controlled trials have been performed comparing the relative efficacy or safety of infliximab and etanercept.
BIW, twice weekly; PASI, psoriasis area severity index.
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also interferes with myeloid CD11cþ DC maturation and
emigration, T-cell activation and emigration, and neutrophil
emigration (Gottlieb et al., 2005).
These authors also show that uninvolved psoriatic skin
contains an increased level of nuclear, activated, phospho-
RelA compared with normal volunteer skin, and that within
the epidermis of psoriatic plaques, there is overexpression of
activated, phospho-RelA as compared to unaffected skin.
Nuclear factor-kB, which is intimately associated with IFN-g,
TNF, and the production of IL-12 and 23 among other
mediators of inflammation and immunity, appears to play a
central function in the psoriatic cascade (Lizzul et al., 2005).
Dermal DCs were observed to overexpress activated,
phospho-RelA in untreated lesional skin, and to become
apoptotic with etanercept treatment. This observation may
partially explain the substantially decreased DC numbers
associated with response to therapy. Infliximab has been
demonstrated to induce apoptosis of T cells in lesional tissue
and of circulating monocytes from patients with Crohn’s
disease (Lugering et al., 2001; ten Hove et al., 2002).
Whether apoptosis is induced in rheumatoid synovial cells by
TNF blockade is still controversial (Pope, 2002; Smeets et al.,
2003). To date, there is no single study that studies the
comparative mechanisms of action of all three TNF blockers
in a single disease.
Finally, understanding differences in the pharmacokinetics
and pharmacodynamics in both blood and target tissues of
psoriasis patients treated with TNF blockers is important. For
example, it may be that higher concentrations of etanercept
are desirable in the skin than in the joints of psoriasis patients
because there is more surface area in the skin than in the
joints. This may be a subject worth exploring in future
studies.
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